Search clinical trials for: Placebo to RO4917838

Total 60137 results

Hoffmann-La Roche

Completed

A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers

Healthy Volunteer

France
Hoffmann-La Roche

Completed

A Pharmacodynamic and Pharmacokinetic Study of RO4917838 in Healthy Volunteers

Healthy Volunteer

France
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers

Healthy Volunteer

China
Hoffmann-La Roche

Completed

A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838

Healthy Volunteer

France, Russian Federation
Hoffmann-La Roche

Completed

A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia

Beta-Thalassemia

Italy, Lebanon, Thailand
Hoffmann-La Roche

Completed

A Study on the Effect of Renal Impairment on the Pharmacokinetics of RO4917838

Healthy Volunteer

France, Russian Federation
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

Schizophrenia

United States, China, Italy, Bulgaria, Russian Federation, Japan, Czech Republic
Hoffmann-La Roche

Completed

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

Obsessive-Compulsive Disorder

United States, Canada
Disc Medicine, Inc

Active, not recruiting

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

Erythropoietic Protoporphyria

United States
Disc Medicine, Inc

Enrolling by invitation

Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP

Erythropoietic Protoporphyria

United States, Australia
Hoffmann-La Roche

Completed

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

Schizophrenia

Finland, Sweden, Korea, Republic of, United States, Colombia, France, Russian Federation, Australia, Hungary, Romania, Mexico, United Kingdom, Argentina, India
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

Schizophrenia

Germany, Spain, Turkey, Canada, United States, Netherlands, Chile, Brazil, Taiwan, Poland, Ukraine, Slovakia, Lithuania, Latvia
Hoffmann-La Roche

Completed

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

Schizophrenia

Germany, Spain, Turkey, Canada, United States, Netherlands, Chile, Brazil, Taiwan, Poland, Ukraine, Slovakia, Lithuania, Latvia
Hoffmann-La Roche

Completed

A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)

Schizophrenia

Korea, Republic of, United States, Hungary, Russian Federation, Argentina, Colombia, India, Australia, Finland, France, Mexico, Romania, Sweden, United Kingdom
Hoffmann-La Roche

Completed

A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Participants With Schizophrenia and Schizoaffective Disorder

Schizophrenia

United States
Hoffmann-La Roche

Completed

A Study of RO4917838 in Combination With Antipsychotic Treatment in Patients With Schizophrenia.

Schizophrenia

United States, Poland, Hungary, Russian Federation, Germany, Austria, France, Brazil, Japan, Mexico
Hoffmann-La Roche

Completed

A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia

Schizophrenia

United States, Italy, China, Japan, Russian Federation, Bulgaria, Czech Republic
Hoffmann-La Roche

Completed

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Healthy Volunteer

United States, France
Noema Pharma AG

Recruiting

Basimglurant in Children, Adolescents, and Young Adults With TSC

Tuberous Sclerosis Complex

United States, India, Israel, Turkey, Italy, Poland, Spain, United Kingdom
Alyatec

Completed

Evaluation of the Nasal and Conjunctival Response in Subjects Allergic to Birch Pollen in the ALYATEC Environmental Exposure Chamber

Allergic Rhinitis | Rhinoconjunctivitis | Allergy to Pollen

France
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Spain, France, Austria, Germany, United States, Hungary, Belgium, Iceland, Netherlands, Denmark, Czechia
CoMentis
Alpharmagen, Inc.

Suspended

Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia

Schizophrenia

United States
Kallyope Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833

Obesity

United States
ReveraGen BioPharma, Inc.
Santhera Pharmaceuticals

Recruiting

A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD)

Becker Muscular Dystrophy

United States, Italy
Novartis Pharmaceuticals

Active, not recruiting

Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD (Lp(a)HORIZON)

Cardiovascular Disease and Lipoprotein(a)

China, Germany, United States, South Africa, Italy, Spain, Belgium, Czechia, Hungary, Japan, Taiwan, Netherlands, Australia, Austria, Canada, France, Israel, Switzerland, United Kingdom, Korea, Republic of, Argentina, Denmark, Greece, Romani... and more
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Hypertension

China
KalVista Pharmaceuticals, Ltd.

Completed

A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation (ACI)

Knee Cartilage Lesion

Austria
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Inhaled AZD8683

Healthy

United Kingdom
Bayer

Recruiting

A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis (SIRIUS)

Thrombolysis | Symptomatic Proximal Deep Vein Thrombosis

Belgium, France, Italy, Netherlands, Canada, Germany
Novartis Pharmaceuticals

Completed

Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Asthma

United States, Belgium, Germany, Israel, Argentina, France, Denmark, Slovakia
KalVista Pharmaceuticals, Ltd.

Completed

A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 in Healthy Volunteers

Hereditary Angioedema

United Kingdom
Novartis Pharmaceuticals

Terminated

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Switzerland, United States, Germany, Singapore, Korea, Republic of, Canada
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Texas Tech University
EHP Labs

Completed

Metabolic Effects of a Thermogenic Ready-to-drink Beverage

Metabolism | Metabolic Rate

United States
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
University of Maryland, Baltimore
Bill and Melinda Gates Foundation

Active, not recruiting

Oral Azithromycin to Prevent Stillbirths and Infant Mortality in Mali (SANTE)

Stillbirths and Infant Mortality

Mali
Cardior Pharmaceuticals GmbH

Active, not recruiting

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (HF-REVERT)

Myocardial Infarction, Acute | Heart Failure, Left Sided

Netherlands, Spain, Hungary, Germany, United Kingdom, Czechia, Poland, Greece
Bayer

Completed

A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses

Hypertension | Chronic Kidney Disease

Germany, Bulgaria
AstraZeneca

Completed

AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease | Lung Disease

Bulgaria, Slovakia
AstraZeneca

Completed

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

Pharmacokinetics | Safety | Pharmacodynamics of AZD7594

United Kingdom
Lohocla Research Corporation
National Institute on Drug Abuse (NIDA)

Recruiting

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

Chronic Pain

United States
Novartis Pharmaceuticals

Terminated

To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

Part 1 - Healthy Volunteers | Part 2 - Patients With Hypertension

United States
Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I) (AUGUST I)

Rheumatoid Arthritis

United States, Canada
Harvard University

Withdrawn

Mindfulness Intervention and Symptom Variability in Hearing

Hearing Loss

United States
AstraZeneca

Completed

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

Schizophrenia

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Primary Biliary Cirrhosis

China

Search clinical trials for: Placebo to RO4917838

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations